Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIDEL vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Atopic dermatitis unresponsive to or intolerant of other topical treatments,Off-label: psoriasis, vitiligo, rosacea, contact dermatitis, lichen sclerosus, cutaneous lupus erythematosus
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Apply a thin layer of 1% cream to affected areas twice daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 30–45 hours (mean 35 hours) following topical application; clinically, twice-daily dosing ensures therapeutic concentrations.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Metabolized primarily by CYP3A4; major metabolite O-demethylated pimecrolimus.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal (negligible, <1% unchanged) and biliary/fecal (approximately 97% as metabolites); less than 1% of the dose is excreted renally as unchanged drug.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
99% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd ~ 10 L/kg (extensive tissue distribution); suggests significant extravascular binding and penetration into tissues.
4-6 L/kg; large Vd indicates extensive tissue distribution
Topical: Systemic bioavailability is approximately 4% (range 1–7%) of applied dose; absorption increases with extent of skin lesion and thickness of application.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
No dose adjustment required for any degree of renal impairment.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No formal studies in hepatic impairment; use caution in severe impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Apply a thin layer of 1% cream twice daily for children aged 2 years and older; not indicated for children under 2 years.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment recommended; apply a thin layer of 1% cream twice daily as for adults.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; use should be limited to short-term and intermittent treatment.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Increased risk of infections (e.g., eczema herpeticum, varicella zoster); avoid use on malignant or premalignant skin conditions; lymphadenopathy; photosensitivity; not recommended in patients with Netherton syndrome; potential for systemic immunosuppression; monitor for local irritation.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to pimecrolimus or any component of the formulation; history of malignancy; application to areas of active infection; Netherton syndrome; immunocompromised patients.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No known food interactions. Avoid grapefruit juice as it may increase drug levels (CYP3A4 inhibition).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be excluded. Avoid in pregnancy unless clearly needed.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Not recommended. Pimecrolimus is excreted in milk in animal studies; unknown in humans. M/P ratio not available. Potential for serious adverse reactions in nursing infants.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dose adjustment necessary; use minimal amount to control symptoms. Systemic absorption is negligible, so pharmacokinetic changes in pregnancy do not alter dosing.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Topical calcineurin inhibitor for atopic dermatitis, reserved as second-line therapy for mild-to-moderate eczema due to boxed warning for rare malignancy risk. Apply thin layer only; avoid occlusive dressings. Do not use in immunocompromised patients. Intermittent use is recommended; continuous long-term use safety not established.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Apply only to affected skin areas; avoid eyes, mouth, and open wounds.,Use for short durations; do not use continuously for extended periods.,Avoid sun exposure and tanning beds; use sunscreen on treated areas.,Do not cover treated skin with bandages or wraps unless instructed.,Report any signs of infection, skin burning, or new skin growths to your doctor.,This drug is for external use only; wash hands after application unless treating hands.,Do not use if you have a weakened immune system or active skin infection.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIDEL vs ABSTRAL, answered by our medical review team.
ELIDEL is a Topical Calcineurin Inhibitor that works by Inhibits T-cell activation by binding to macrophilin-12 (FKBP-12) and inhibiting calcineurin, thereby blocking cytokine transcription.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIDEL and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIDEL is: Apply a thin layer of 1% cream to affected areas twice daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIDEL and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIDEL is classified as Category C. FDA Pregnancy Category C. Systemic exposure is minimal after topical application, but animal studies have shown developmental toxicity. No adequate human studies; risk cannot be ex. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.